Chemotherapy in colorectal cancer: New options and new challenges

British Medical Bulletin

Volumn 64, Issue , 2002, Pages 159-180

  Chau, Ian ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; ANGIOGENESIS INHIBITOR; CAPECITABINE; CISPLATIN; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; MATRIX METALLOPROTEINASE INHIBITOR; OXALIPLATIN; PROSTAGLANDIN SYNTHASE; RALTITREXED; SEMUSTINE; TEGAFUR; UFT; VINCRISTINE;

ALOPECIA; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DYSESTHESIA; FEVER; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; LUNG EMBOLISM; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; SEPSIS; STOMATITIS; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS;

EID: 0036034562     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/bmb/64.1.159     Document Type: Review

References (60)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000-Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No.5, Lyon:IARCPress, 2001
2. Martenson JA, Willett CG, Sargent DJ et al. A phase III study of adjuvant radiation therapy (RT), 5-Fluorouracil (5-FU), and levamisole (LEV) vs 5-FU and LEV in selected patients with resected, high risk colon cancer: Initial results of Int 0130. Proc Am Soc Clin Oncol 1999; 18: 235a
3. Ries LAG, Eisner MP, Kosary CL et al. (eds) SEER Cancer Statistic Review, 1973-1999. Bethesda, MD: National Cancer Institute, 2002 〈http://seer.cancer.gov/csr/1973-1999/〉
4. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-44
5. Haller D, Catalano PJ, Macdonald JS, Mayer RJ. Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: Five year final report of Int-0089. Proc Am Soc Clin Oncol 1998;17:256a
6. Moertel CG, Fleming TR, Macdonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 1995;122:321-6
7. O'Connell MJ, Mailliard JA, Kahn MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15:246-50
8. O'Connell MJ, Laurie JA, Kahn M et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16: 295-300
9. Wolmark N, Fisher B, Rockette H et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: Results from NSABP protocol C-01. J Natl Cancer Inst 1988; 80: 30-6
10. Wolmark N, Rockette H, Wickerham DL et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: Preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990; 8: 1466-75
11. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11: 1879-87
12. Wolmark N, Bryant J, Smith R et al. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 1998; 90: 1810-6
13. Wolmark N, Rockette H, Mamounas E et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17: 3553-9
14. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-50
15. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 2002; 20: 1192-202
16. Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: Improved survival in stage II and III. Br J Cancer 2001; 85: 1437-43
17. Porschen R, Bermann A, Loffler T et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: Results of the trial adjCCA-01. J Clin Oncol 2001; 19: 1787-94
18. Staib L, Link KH, Beget HG. Toxicity and effects of adjuvant therapy in colon cancer: Results of the German prospective, controlled randomized multicenter trial FOGT-1. J Gastrointest Surg 2001; 5: 275-81
19. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial. Lancet 2000; 355: 1588-96
20. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999;17:1356-63
21. Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17: 1349-55
22. Buyse M, Piedbois P. Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 2001; 28: 20-4
23. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-8
24. Saini A, Cunningham D, Norman A et al. Multicentre randomized trial of protracted venous infusion (PVI) 5 FU compared to 5 FU/folinic Acid (5FU/FA) as adjuvant therapy for colorectal cancer. Proc Am Soc Clin Oncol 2000; 19: 240a
25. Andre T, Colin P, Louver C et al. Phase III trial (GERCOR C96.1) comparing bimonthly LV5FU2 to monthly 5FU-leucovorin high dose (LV hd) in patients with Dukes' B2 and C colon cancer. Proc Am Soc Clin Oncol 2002; 21: 133a
26. Poplin E, Benedetti J, Estes N et al. Phase III randomized trial of bolus 5-FU/leucovorin/-levamisole versus 5-FU continuous infusion/levamisole as adjuvant therapy for high risk colon cancer (SWOG 9415/INT-0153). Proc Am Soc Clin Oncol 2000; 19: 240a
27. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-92
28. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001; 19: 4097-106
29. Douillard J-Y, Hoff PM, Skillings JR et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3605-16
30. Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3617-27
31. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-8
32. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-7
33. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-12
34. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-14
35. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 2001;19:3801-7
36. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47
37. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-47
38. de Gramont A, Boni C, Navarro M et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Safety results of the international randomized MOSAIC trial. Proc Am Soc Clin Oncol 2002; 21: 132a
39. Riethmuller G, Holz E, Schlimok G et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998; 16: 1788-94
40. Punt CJ, Nagy A, Douillard J-Y et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: A randomised study. Lancet 2002;360:671-2
41. Fields A, Keller AM, Schwartzberg L et al. Edrecolomab (17-1A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: Results of a randomised north American phase III study. Proc Am Soc Clin Oncol 2002; 21: 128a
42. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992;10:896-903
43. Schuller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-7
44. Twelves C. Capecitabine as first-line treatment in colorectal cancer pooled data from two large, phase III trials. Eur J Cancer 2002; 38 (Suppl 2): 15-20
45. Borner MM, Schoffski P, de Wit R et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349-58
46. Schilsky RL, Levin J, West WH et al. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 2002; 20: 1519-26
47. Van Cutsem E, Sorensen J, Cassidy J et al. International phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (iv) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer. Proc Am Soc Clin Oncol 2001; 20: 131a
48. Vanhoefer U, Harstrick A, Achterrath W et al. Irinotecan in the treatment of colorectal cancer: Clinical overview. J Clin Oncol 2001; 19: 1501-18
49. Cvitkovic E, Bekradda M. Oxaliplatin: A new therapeutic option in colorectal cancer. Semin Oncol 1999; 26: 647-62
50. Goldberg RM, Morton RF, Sargent DJ et al. N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer. Initial toxicity and response data from a GI Intergroup study. Proc Am Soc Clin Oncol 2002; 21: 128a
51. Achille E, Tournigand C, Andre T et al. FOLFIRI then FOLFOX or FOLFOX then FOLFIRI in metastatic colorectal cancer: Results of a phase III trial. Eur J Cancer 2001; 37 (Suppl. 6): S289
52. Becouarn Y, Gamelin E, Coudert B et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 2001; 19: 4195-201
53. Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. J Clin Oncol 2002; 20: 165-72
54. Bleiberg H, Di Leo A, Rothenberg ML et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin. J Clin Oncol 2002; 20: 1145-6
55. Borner MM, Dietrich D, Stupp R et al. Phase II study of capecitabine and oxaliplatin in first-and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20: 1759-66
56. Kerr D, Ten Bokkel Huinink WW, Ferry D et al. A phase I/II study of CPT- 11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer. Proc Am Soc Clin Oncol 2002; 21: 161a
57. Cunningham D, Zalcberg J, Maroun J et al. Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. A review of phase II/III trials. Eur J Cancer 2002; 38: 478-86
58. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N EnglJ Med 1990; 322: 352-8
59. Wolmark N, Colangelo L, Wieand S. National Surgical Adjuvant Breast and Bowel Project trials in colon cancer. Semin Oncol 2001; 28: 9-13
60. Marsoni S. Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. Semin Oncol 2001;28:14-9